A Case With New-Onset Neuromyelitis Optica Spectrum Disorder Following COVID-19 mRNA BNT162b2 Vaccination

Area of Science:

• Neurology
• Immunology
• Vaccinology

Background:

• The COVID-19 pandemic highlighted the critical role of vaccines in global health.
• Messenger RNA (mRNA) vaccines represent a novel immunization strategy requiring ongoing safety monitoring.
• Active immunization through vaccination is crucial for controlling infectious diseases.

Observation:

• A previously healthy 43-year-old female experienced optic neuritis 24 hours post-BNT162b2 mRNA COVID-19 vaccination.
• The patient subsequently had a transverse myelitis attack.
• Elevated anti-Aquaporin-4 (AQP4) antibody titers confirmed neuromyelitis optica spectrum disorder (NMOSD).

Findings:

• The BNT162b2 vaccine is identified as a potential trigger for neuromyelitis optica spectrum disorder in this case.
• This represents a rare adverse event potentially linked to mRNA vaccine administration.
• The event's coincidental nature requires further research to confirm causality.

Implications:

• While this rare event has no immediate implications for current vaccine administration practices, it underscores the need for vigilance.
• Further research is essential to understand the impact of mRNA vaccines on both humoral and cell-mediated immunity.
• Continued surveillance for rare neurological events following vaccination is important for vaccine safety monitoring.